NCT01688011 is a clinical trial of Luspatercept in Primary Myelofibrosis, sponsored by Celgene.

Who is sponsoring NCT01688011?

NCT01688011 is sponsored by Celgene.

What drugs are being tested in NCT01688011?

Interventions in NCT01688011: Luspatercept.

What condition does NCT01688011 study?

NCT01688011 studies Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute.

Is NCT01688011 still recruiting?

NCT01688011 is currently terminated. Last updated 3 July 2025.

Last reviewed 2025-07-03 · How we verify

NCT01688011

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Connect® Myeloid Disease Registry

Terminated Last updated 3 July 2025

What this trial tests

trial testing Luspatercept in Primary Myelofibrosis in 2,013 participants. Terminated before completion.

Timeline

12 December 2013

Primary endpoint
18 October 2024

18 October 2024

Quick facts

Lead sponsor	Celgene
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	2,013
Start date	12 December 2013
Primary completion	18 October 2024
Estimated completion	18 October 2024
Sites	158 locations across Puerto Rico, United States

Drugs / interventions tested

Luspatercept (LUSPATERCEPT) — full drug profile →

Conditions studied

Primary Myelofibrosis — all drugs for Primary Myelofibrosis →
Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
Leukemia, Myeloid, Acute — all drugs for Leukemia, Myeloid, Acute →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Primary Myelofibrosis or Myelodysplastic Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP, Abedi M, Bejar R, Cogle CR, et al · · 2016 · cited 10× · PMID 27538433 · DOI 10.1186/s12885-016-2710-6
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect<sup>®</sup> MDS/AML Disease Registry.
Pollyea DA, George TI, Abedi M, Bejar R, et al · · 2020 · cited 8× · PMID 35847712 · DOI 10.1002/jha2.16
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care.
Tomlinson B, de Lima M, Cogle CR, Thompson MA, et al · · 2023 · cited 7× · PMID 37086851 · DOI 10.1016/j.jtct.2023.04.011
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Ma X, Steensma DP, Scott BL, Kiselev P, et al · · 2018 · cited 7× · PMID 30037860 · DOI 10.1136/bmjopen-2017-019955
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
Patel JL, Abedi M, Cogle CR, Erba HP, et al · · 2021 · cited 6× · PMID 33220019 · DOI 10.1111/ijlh.13400
P589: IMPLICATIONS OF REGISTRY DATA FOR ACUTE MYELOID LEUKEMIA (AML) TREATMENT AND CARE DURING THE COVID-19 PANDEMIC
Scott B, Sekeres M, Garcia-Manero G, Grinblatt D, et al · · 2023
Genomic Data Heterogeneity across Molecular Diagnostic Laboratories: A Real-World Connect Myeloid Disease Registry Perspective on Variabilities in Genomic Assay Methodology and Reporting.
Patel JL, Erba HP, Savona MR, Grinblatt DL, et al · · 2023 · PMID 37517825 · DOI 10.1016/j.jmoldx.2023.05.002
Abstract Book for the 27th Congress of the European Hematology Association
· 2022

Verify or expand the search:

Other trials of Luspatercept

Trials testing the same drug.

NCT07463820 — A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Tre · Phase 2 · not yet recruiting
NCT07450313 — The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT · Phase 2 · not yet recruiting
NCT07215975 — A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East · recruiting
NCT07465029 — A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in · active not recruiting
NCT07362095 — Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) · Phase 1, PHASE2 · recruiting

Other recruiting trials for Primary Myelofibrosis

Currently open trials in the same condition.

NCT07228624 — Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas · Phase 2 · recruiting
NCT06661915 — A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) · Phase 2 · recruiting
NCT06468033 — P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk · Phase 3 · recruiting
NCT06517875 — Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis · Phase 2 · recruiting
NCT06343805 — A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) · Phase 1 · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01688011 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 3 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01688011.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing